Generic Drug Labeling

AAM Statement on FDA Withdrawal of Generic Drug Labeling Rule

WASHINGTON DC (December 13, 2018) – “AAM applauds FDA Commissioner Scott Gottlieb and the agency for prioritizing consumer access to safe, high-quality, affordable generic medicines by withdrawing its proposed labeling rule. The agency correctly recognized the need for consistency and the potential for adverse consequences. The FDA’s action further exemplifies its focus on the best interest of the public’s health and provides patients with the utmost confidence in their health care choices.”

Subscribe to Generic Drug Labeling

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.